Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Locacorten Tar + Locasalen is a combination topical therapy used primarily for the treatment of refractory psoriasis. This regimen involves the application of Locacorten Tar ointment (containing flumethasone pivalate and tar) under occlusive dressings at night, and Locasalen ointment (containing flumethasone pivalate and salicylic acid) as an open treatment during the day. The therapeutic effect is attributed to three main actions: - The anti-epidermoplastic effect of flumethasone pivalate, a moderately potent synthetic glucocorticoid that acts as a glucocorticoid receptor agonist with anti-inflammatory, antipruritic, and vasoconstrictive properties. - The squamolytic (keratolytic) action of salicylic acid in Locasalen. - The keratoplastic action of coal tar in Locacorten Tar. This combination approach allows for effective management of psoriatic lesions without requiring hospitalization by leveraging both occlusive and non-occlusive methods[1][2]. Flumethasone pivalate reduces inflammation by modulating immune responses via glucocorticoid receptors[3][8], while salicylic acid helps remove scales through its keratolytic activity. Coal tar exerts antiproliferative effects on epidermal cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on locacorten tar + locasalen.